Amneal to Report First Quarter 2026 Results on May 1, 2026
Rhea-AI Summary
Amneal (NASDAQ: AMRX) will release its first quarter 2026 financial results on Friday, May 1, 2026 before market open. The company will host a live audio webcast at 8:30 a.m. ET, accessible via the Investor Relations site, with a conference line and replay posted after the call.
Dial-in details and the access code 458312872 are provided for conference access; registration is available on the Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – AMRX
In the Apr 8 session, AMRX gained 3.17%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Earnings date notice | Neutral | +1.9% | Set date and webcast details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The prior earnings-date announcement on Jan 27, 2026 saw a modest positive +1.92% move, suggesting neutral-to-slightly-positive trading around scheduling headlines.
Recent history shows Amneal using scheduled events and solid fundamentals to build its profile. The last earnings-date notice on Jan 27, 2026 preceded Q4 and full-year 2025 results, where the company reported $3.02 billion in 2025 net revenue and GAAP net income of $72 million. Guidance for 2026 called for $3.05–3.15 billion in revenue and $720–760 million adjusted EBITDA. Today’s first‑quarter 2026 earnings date continues that cadence of regular financial communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 458312872. A replay of the conference call will be posted shortly after the call.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
